<DOC>
	<DOCNO>NCT00002680</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may kill tumor cell . PURPOSE : Phase II trial study effectiveness sequential high-dose chemotherapy follow peripheral stem cell transplantation treat patient metastatic breast cancer respond chemotherapy .</brief_summary>
	<brief_title>Sequential High-Dose Chemotherapy Stem Cell Transplantation Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility efficacy sequential high-dose cyclophosphamide , melphalan , thiotepa plus autologous peripheral blood stem cell rescue patient metastatic breast cancer ongoing objective response prior induction chemotherapy . OUTLINE : Patients receive sequential therapy begin regimen A . Regimen A : Patients receive cyclophosphamide IV 1 hour every 6 hour 4 dos within 36 hour . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin 2 day completion cyclophosphamide continue autologous peripheral blood stem cell ( PBSC ) harvest . Regimen B : Beginning least 3 week initiation regimen A , patient receive melphalan IV day 1 2 . Beginning day 4 , portion PBSC reinfused . Patients receive G-CSF SC daily begin day 4 continue least day 10 . Regimen C : Beginning least 3 week initiation regimen B , patient receive thiotepa IV 2 hour day 1 2 . Beginning day 5 , remain PBSC reinfused . Patients receive G-CSF SC daily begin day 5 continue blood count recover . During regimens A , B , C , G-CSF must discontinue least 2 day administration chemotherapy . Regimen D : After recovery chemotherapy , patient hormone receptor-positive tumor prior refractoriness hormonal therapy receive oral tamoxifen daily , patient prior failure tamoxifen receive oral megestrol 4 time daily . Patients undergo irradiation sit prior cutaneous , nodal , bone , soft tissue bulk disease resection residual lesion . Patients follow weekly 1 month , biweekly 2 month , monthly 5 month , bimonthly 1 year . PROJECTED ACCRUAL : A minimum 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IV breast carcinoma consider incurable standard treatment Ongoing objective response prior induction chemotherapy require No brain metastasis Hormone receptor status : Estrogen progesterone receptor status know PATIENT CHARACTERISTICS : Age : Over 18 Sex : Not specify Menopausal status : Not specify Performance status : Karnofsky 90100 % Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( unless due benign congenital hyperbilirubinemia ) PT aPTT normal Liver biopsy normal serologic evidence active hepatitis B C Renal : Creatinine great 1.2 mg/dL Cardiovascular : No active heart disease LVEF least 50 % abnormal wall motion MUGA scan Pulmonary : DLCO normal Other : Nutritional status adequate ( 1,000 calories/day orally ) HIV negative No active serious medical psychiatric disease No prior malignancy except basal cell skin cancer carcinoma situ cervix uteri Not pregnant Negative pregnancy test Fertile patient must use effective barrier contraception 2 year study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior mitomycin nitrosourea No prior anthracycline great 500/m2 unless previously receive dexrazoxane At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pelvis brain Surgery : At least 2 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>